Skip to main content
SpringerLink
Log in

Behandlung unter besonderen Bedingungen (Modul 4c)

  • Chapter
  • First Online:
S3-Leitlinie Schizophrenie

  • 3893 Accesses

Zusammenfassung

Menschen mit Schizophrenie können weitere psychische Störungen aufweisen, die den Erkrankungsverlauf und den Behandlungserfolg ungünstig beeinflussen können. Zu diesen komorbiden Störungen oder komorbid auftretenden Symptomen zählen u. a.:

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):383–402

    Article  PubMed  Google Scholar 

  2. Tsai J, Rosenheck RA (2013) Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res 210(1):16–20

    Article  PubMed  PubMed Central  Google Scholar 

  3. Green AI, Canuso CM, Brenner MJ, Wojcik JD (2003) Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26(1):115–139

    Article  PubMed  Google Scholar 

  4. Brennan PA, Mednick SA, Hodgins S (2000) Major mental disorders and criminal violence in a Danish birth cohort. Arch Gen Psychiatry 57(5):494–500

    Article  CAS  PubMed  Google Scholar 

  5. Tiihonen J, Isohanni M, Rasanen P, Koiranen M, Moring J (1997) Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort. Am J Psychiatry 154(6):840–845

    Article  CAS  PubMed  Google Scholar 

  6. Walsh E, Buchanan A, Fahy T (2002) Violence and schizophrenia: examining the evidence. Br J Psychiatry 180:490–495

    Article  PubMed  Google Scholar 

  7. Choe JY, Teplin LA, Abram KM (2008) Perpetration of violence, violent victimization, and severe mental illness: balancing public health concerns. Psychiatr Serv 59(2):153–164

    Article  PubMed  PubMed Central  Google Scholar 

  8. Steinert T, Bergbauer G, Schmid P, Gebhardt RP (2007) Seclusion and restraint in patients with schizophrenia: clinical and biographical correlates. J Nerv Ment Dis 195(6):492–496

    Article  PubMed  Google Scholar 

  9. Campbell LA, Kisely SR (2009) Advance treatment directives for people with severe mental illness. Cochrane Database Syst Rev 1:CD005963

    Google Scholar 

  10. Farrelly S, Brown GE, Flach C, Barley E, Laugharne R, Henderson C (2013) User-held personalised information for routine care of people with severe mental illness. Cochrane Database Syst Rev 10:CD001711

    Google Scholar 

  11. Du M, Wang X, Yin S, Shu W, Hao R, Zhao S, Rao H, Yeung WL, Jayaram MB, Xia J (2017) De-escalation techniques for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 4:CD009922

    PubMed  Google Scholar 

  12. de Jong MH, Kamperman AM, Oorschot M, Priebe S, Bramer W, van de Sande R, Van Gool AR, Mulder CL (2016) Interventions to reduce compulsory psychiatric admissions: a systematic review and meta-analysis. JAMA Psychiatry 73(7):657–664

    Article  PubMed  Google Scholar 

  13. Beghi M, Peroni F, Gabola P, Rossetti A, Cornaggia CM (2013) Prevalence and risk factors for the use of restraint in psychiatry: a systematic review. Riv Psichiatr 48(1):10–22

    PubMed  Google Scholar 

  14. DGPPN (2006) S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Gaebel Wf, Falkai, P., Weinmann, S., Wobrock T., editor. Steinkopff, Darmstadt

    Google Scholar 

  15. NICE (2015) Violence and aggression: short-term management in mental health, health and community settings. NICE Guideline, No. 10. National Collaborating Centre for Mental Health (UK). London: British Psychological Society; 2015

    Google Scholar 

  16. DGPPN (2009) Therapeutische Maßnahmen bei aggressivem Verhalten in der Psychiatrie und Psychotherapie. https://www.dgppn.de/_Resources/Persistent/fa128e27b086d7a72813034b7532cee62c025848/S2-LL_Aggres.Verhalten_Kurzversion_21.10.2009.pdf

  17. DGPPN. S3 Leitlinie (2018) „Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens bei Erwachsenen“. https://www.dgppn.de/_Resources/Persistent/154528053e2d1464d9788c0b2d298ee4a9d1cca3/S3%20LL%20Verhinderung%20von%20Zwang%20LANG%2BLITERATUR%20FINAL%2010.9.2018.pdf

  18. SIGN SIGN (2013) SIGN 131 • Management of schizophrenia • A national clinical guideline

    Google Scholar 

  19. Huf G, Alexander J, Gandhi P, Allen MH (2016) Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 11:CD005146

    PubMed  Google Scholar 

  20. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE (2017) Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 7:CD009377

    PubMed  Google Scholar 

  21. Gault TI, Gray SM, Vilke GM, Wilson MP (2012) Are oral medications effective in the management of acute agitation? J Emerg Med 43(5):854–859

    Article  PubMed  Google Scholar 

  22. Ahmed U, Jones H, Adams CE (2010) Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 4:CD007445

    Google Scholar 

  23. Khokhar MA, Rathbone J (2016) Droperidol for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 12:CD002830

    PubMed  Google Scholar 

  24. Jayakody K, Gibson RC, Kumar A, Gunadasa S (2012) Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev 4:CD000525

    Google Scholar 

  25. Gillies D, Sampson S, Beck A, Rathbone J (2013) Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 9:CD003079

    PubMed  Google Scholar 

  26. Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23(9):1023–1033

    Article  CAS  PubMed  Google Scholar 

  27. Keating GM (2013) Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs 27(6):479–489

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia. Cochrane Database Syst Rev 11:CD004028

    PubMed  Google Scholar 

  29. Leucht S, Helfer B, Dold M, Kissling W, McGrath J (2014) Carbamazepine for schizophrenia. Cochrane Database Syst Rev 5:CD001258

    Google Scholar 

  30. Müller MJ, Benkert O (2017) Pharmakotherapie psychiatrischer Notfallsituationen. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd 11. Springer, Berlin/Heidelberg, S 839–887

    Chapter  Google Scholar 

  31. Schmidt A, Fischer P, Wally B, Scharfetter J (2017) Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval. Neuropsychiatrie 31(4):172–175

    Article  PubMed  Google Scholar 

  32. Soehner AM, Kaplan KA, Harvey AG (2013) Insomnia comorbid to severe psychiatric illness. Sleep Med Clin 8(3):361–371

    Article  PubMed  PubMed Central  Google Scholar 

  33. Cohrs S (2008) Sleep disturbances in patients with schizophrenia impact and effect of antipsychotics. CNS Drugs 22(11):939–962

    Article  CAS  PubMed  Google Scholar 

  34. Kaskie RE, Graziano B, Ferrarelli F (2017) Schizophrenia and sleep disorders: links, risks, and management challenges. Nat Sci Sleep 9:227–239

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chiu VW, Harvey RH, Sloan NB, Ree M, Lin A, Janca A, Waters F (2015) Cognitive and behavioral factors associated with insomnia in inpatients with schizophrenia and related psychoses. J Nerv Ment Dis 203(10):798–803

    Article  PubMed  Google Scholar 

  36. Chiu VW, Ree M, Janca A, Waters F (2016) Sleep in schizophrenia: exploring subjective experiences of sleep problems, and implications for treatment. Psychiatry Q 87(4):633–648

    Article  Google Scholar 

  37. Freeman D, Waite F, Startup H, Myers E, Lister R, McInerney J, Harvey AG, Geddes J, Zaiwalla Z, Luengo-Fernandez R, Foster R, Clifton L, Yu LM (2015) Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. Lancet Psychiatry 2(11):975–983

    Article  PubMed  PubMed Central  Google Scholar 

  38. DGSM (2009) Nicht erholsamer Schlaf/Schlafstörunge. http://www.dgsm.de/downloads/akkreditierung_ergebnisqualitaet/S3-Leitlinie_Nicht_erholsamer_Schlaf-Schlafstoerungen.pdf

  39. Müller MJ, Benkert O (2017) Antipsychotika. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd 11. Springer, Berlin/Heidelberg, S 269–488

    Chapter  Google Scholar 

  40. Myers E, Startup H, Freeman D (2011) Cognitive behavioural treatment of insomnia in individuals with persistent persecutory delusions: a pilot trial. J Behav Ther Exp Psychiatry 42(3):330–336

    Article  PubMed  PubMed Central  Google Scholar 

  41. NICE TNIfHaCE (2014) Psychosis and schizophrenia in adults: prevention and management

    Google Scholar 

  42. Gibson RC, Walcott G (2008) Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 4:CD006570

    Google Scholar 

  43. Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G (2014) A clinical review of the treatment of catatonia. Front Psychiatry 5:181

    Article  PubMed  PubMed Central  Google Scholar 

  44. Leroy A, Naudet F, Vaiva G, Francis A, Thomas P, Amad A (2017) Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268(7):675–687

    Article  PubMed  Google Scholar 

  45. Nordentoft M, Jeppesen P, Abel M, Kassow P, Petersen L, Thorup A, Krarup G, Hemmingsen R, Jorgensen P (2002) OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 43:s98–s106

    Article  CAS  PubMed  Google Scholar 

  46. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, Schizophrenia WTFoTGf (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: update 2015 Management of special circumstances: depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170

    Article  PubMed  Google Scholar 

  47. Caldwell CB, Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16(4):571–589

    Article  CAS  PubMed  Google Scholar 

  48. Siris SG (2001) Suicide and schizophrenia. J Psychopharmacol 15(2):127–135

    Article  CAS  PubMed  Google Scholar 

  49. Meltzer HY (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 66(4):530–533

    Article  PubMed  Google Scholar 

  50. Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, Krausz M, Lester D, Meltzer HY, Modestin J, Montross LP, Mortensen PB, Munk-Jorgensen P, Nielsen J, Nordentoft M, Saarinen PI, Zisook S, Wilson ST, Tatarelli R (2007) Suicide risk in schizophrenia: learning from the past to change the future. Ann General Psychiatry 6:10

    Article  Google Scholar 

  51. Pompili M, Lester D, Grispini A, Innamorati M, Calandro F, Iliceto P, De Pisa E, Tatarelli R, Girardi P (2009) Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res 167(3):251–257

    Article  PubMed  Google Scholar 

  52. Beautrais AL (2001) Suicides and serious suicide attempts: two populations or one? Psychol Med 31(5):837–845

    Article  CAS  PubMed  Google Scholar 

  53. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research T (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93

    Article  PubMed  Google Scholar 

  54. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric A, Steering Committee on Practice G (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56

    PubMed  Google Scholar 

  55. Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V (2012) The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 27(2):129–141

    Article  CAS  PubMed  Google Scholar 

  56. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, del Miller D, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68(11):1751–1762

    Article  CAS  PubMed  Google Scholar 

  57. Kelly DL, Wehring HJ, Vyas G (2012) Current status of clozapine in the United States. Shanghai Arch Psychiatry 24(2):110–113

    PubMed  PubMed Central  Google Scholar 

  58. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82–91

    Article  CAS  PubMed  Google Scholar 

  59. Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, Kumar V (2004) Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry 65(5):679–685

    Article  CAS  PubMed  Google Scholar 

  60. Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73(2–3):139–145

    Article  PubMed  Google Scholar 

  61. Haas SJ, Dennekamp MN, Wolfe R, Vos T (2006) Beware the meta-analysis – clozapine and suicidal ideation. Schizophr Res 86(1–3):331–332

    Article  PubMed  Google Scholar 

  62. Siris SG (2000) Depression in schizophrenia: perspective in the era of „Atypical“ antipsychotic agents. Am J Psychiatry 157(9):1379–1389

    Article  CAS  PubMed  Google Scholar 

  63. Siris SG (1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 17(1):75–98

    Article  CAS  PubMed  Google Scholar 

  64. Hor K, Taylor M (2010) Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 24(4 Suppl):81–90

    Article  PubMed  PubMed Central  Google Scholar 

  65. Upthegrove R, Marwaha S, Birchwood M (2017) Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull 43(2):240–244

    PubMed  Google Scholar 

  66. Dutta R, Murray RM, Allardyce J, Jones PB, Boydell J (2011) Early risk factors for suicide in an epidemiological first episode psychosis cohort. Schizophr Res 126(1–3):11–19

    Article  PubMed  Google Scholar 

  67. DGPPN (2015) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depressionen – Langfassung, 2. Aufl. 2015 Version 3

    Google Scholar 

  68. Lako IM, Bruggeman R, Knegtering H, Wiersma D, Schoevers RA, Slooff CJ, Taxis K (2012) A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord 140(1):38–47

    Article  PubMed  Google Scholar 

  69. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, Engel RR, Leucht S (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9):876–886

    Article  PubMed  Google Scholar 

  70. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14(4):429–447

    Article  CAS  PubMed  Google Scholar 

  71. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  CAS  PubMed  Google Scholar 

  72. Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang Fleischhacker W, Kahn RS, Peuskens J, Group ES (2012) Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol 22(12):875–882

    Article  CAS  PubMed  Google Scholar 

  73. Wykes T, Steel C, Everitt B, Tarrier N (2008) Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 34(3):523–537

    Article  PubMed  Google Scholar 

  74. Opoka SM, Lincoln TM (2017) The effect of cognitive behavioral interventions on depression and anxiety symptoms in patients with schizophrenia spectrum disorders: a systematic review. Psychiatr Clin North Am 40(4):641–659

    Article  PubMed  Google Scholar 

  75. Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ (2015) Lithium for schizophrenia. Cochrane Database Syst Rev 10:CD003834

    Google Scholar 

  76. Leucht S, Kissling W, McGrath J (2004) Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 65(2):177–186

    Article  CAS  PubMed  Google Scholar 

  77. Leucht S, Kissling W, McGrath J (2007) Lithium for schizophrenia. Cochrane Database Syst Rev 3:CD003834

    Google Scholar 

  78. van den Berg DP, de Bont PA, van der Vleugel BM, de Roos C, de Jongh A, Van Minnen A, van der Gaag M (2015) Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial. JAMA Psychiatry 72(3):259–267

    Article  PubMed  Google Scholar 

  79. Conus P, Cotton S, Schimmelmann BG, McGorry PD, Lambert M (2010) Pretreatment and outcome correlates of sexual and physical trauma in an epidemiological cohort of first-episode psychosis patients. Schizophr Bull 36(6):1105–1114

    Article  PubMed  Google Scholar 

  80. Bonoldi I, Simeone E, Rocchetti M, Codjoe L, Rossi G, Gambi F, Balottin U, Caverzasi E, Politi P, Fusar-Poli P (2013) Prevalence of self-reported childhood abuse in psychosis: a meta-analysis of retrospective studies. Psychiatry Res 210(1):8–15

    Article  PubMed  Google Scholar 

  81. Fusar-Poli P, Tantardini M, De Simone S, Ramella-Cravaro V, Oliver D, Kingdon J, Kotlicka-Antczak M, Valmaggia L, Lee J, Millan MJ, Galderisi S, Balottin U, Ricca V, McGuire P (2017) Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 40:65–75

    Article  CAS  PubMed  Google Scholar 

  82. Bechdolf A, Thompson A, Nelson B, Cotton S, Simmons MB, Amminger GP, Leicester S, Francey SM, McNab C, Krstev H, Sidis A, McGorry PD, Yung AR (2010) Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. Acta Psychiatr Scand 121(5):377–384

    Article  CAS  PubMed  Google Scholar 

  83. Braga RJ, Reynolds GP, Siris SG (2013) Anxiety comorbidity in schizophrenia. Psychiatry Res 210(1):1–7

    Article  PubMed  Google Scholar 

  84. Freeman D, Garety P (2014) Advances in understanding and treating persecutory delusions: a review. Soc Psychiatry Psychiatr Epidemiol 49(8):1179–1189

    Article  PubMed  PubMed Central  Google Scholar 

  85. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37(4):811–821

    Article  PubMed  Google Scholar 

  86. DGPPN (2014) S3 Leitlinie Behandlung von Angststörungen. http://www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_Angstst%C3%B6rungen_2014-05_2.pdf

  87. Bosanac P, Castle D (2015) How should we manage anxiety in patients with schizophrenia? Australas Psychiatry 23(4):374–377

    Article  PubMed  Google Scholar 

  88. Swets M, Dekker J, van Emmerik-van Oortmerssen K, Smid GE, Smit F, de Haan L, Schoevers RA (2014) The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophr Res 152(2–3):458–468

    Google Scholar 

  89. Mahendran R, Liew E, Subramaniam M (2007) De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry 68(4):542–545

    Article  CAS  PubMed  Google Scholar 

  90. Poyurovsky M, Weizman A, Weizman R (2004) Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 18(14):989–1010

    Article  CAS  PubMed  Google Scholar 

  91. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003) Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuro-Psychopharmacol Biol Psychiatry 27(3):333–346

    Article  Google Scholar 

  92. Reznik I, Mester R, Kotler M, Weizman A (2001) Obsessive-compulsive schizophrenia: a new diagnostic entity? J Neuropsychiatry Clin Neurosci 13(1):115–116

    Article  CAS  PubMed  Google Scholar 

  93. Bottas A, Cooke RG, Richter MA (2005) Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci 30(3):187–193

    PubMed  PubMed Central  Google Scholar 

  94. DGPPN (2014) S3-Leitlinie Zwangsstörungen. http://www.awmf.org/uploads/tx_szleitlinien/038_017l_S3_Zwangsst%C3%B6rungen_2013.pdf

  95. NICE TNIfHaCE (2005) Obsessive-compulsive disorder and body dysmorphic disorder: treatment. https://www.nice.org.uk/guidance/cg31

  96. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23(2):195–201

    Article  CAS  PubMed  Google Scholar 

  97. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Morrison RL, Yadalam KG (1990) Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 16(1):31–56

    Article  CAS  PubMed  Google Scholar 

  98. Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT, Genomic Psychiatry Cohort C (2014) Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71(3):248–254

    Article  PubMed  PubMed Central  Google Scholar 

  99. McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K (2014) Cannabis and schizophrenia. Cochrane Database Syst Rev 10:CD004837

    Google Scholar 

  100. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264(19):2511–2518

    Article  CAS  PubMed  Google Scholar 

  101. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002) Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 252(2):86–92

    Article  CAS  PubMed  Google Scholar 

  102. Ruther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Moller HJ, European Psychiatric A (2014) EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 29(2):65–82

    Article  CAS  PubMed  Google Scholar 

  103. DGPPN (2015) Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums. Batra A, Hoch E, Mann K, Petersen KU (Hrsg) Springer, Berlin/Heidelberg

    Google Scholar 

  104. Drake RE, Mueser KT (2001) Managing comorbid schizophrenia and substance abuse. Curr Psychiatry Rep 3(5):418–422

    Article  CAS  PubMed  Google Scholar 

  105. Drake RE, Mueser KT (2000) Psychosocial approaches to dual diagnosis. Schizophr Bull 26(1):105–118

    Article  CAS  PubMed  Google Scholar 

  106. Arndt S, Tyrrell G, Flaum M, Andreasen NC (1992) Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med 22(2):379–388

    Article  CAS  PubMed  Google Scholar 

  107. DGPPN (2016) In: AWMF, DGPPN (Hrsg) Screening, Diagnose und Behandlung alkoholbezogener Störungen. Springer, Berlin/Heidelberg

    Google Scholar 

  108. Owen C, Rutherford V, Jones M, Tennant C, Smallman A (1997) Noncompliance in psychiatric aftercare. Community Ment Health J 33(1):25–34

    Article  CAS  PubMed  Google Scholar 

  109. Dickey B, Azeni H (1996) Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 86(7):973–977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Rosenthal RN, Westreich LM (1999) Treatment of persons with dual diagnosis of substance use disorders and others psychological problems. In: McCrady BS, Epstein EE (Hrsg) A comprehensive guidebook, Bd 1. Oxford University Press, New York, S 439–476

    Google Scholar 

  111. Gouzoulis-Mayfrank E (2003) Komorbidität Psychose und Sucht. Von den Grundlagen zur Praxis. Steinkopf, Darmstadt

    Book  Google Scholar 

  112. D’Amelio R, Behrendt B, Wobrock T (2007) Psychoedukation. Schizophrenie und Sucht. Manual zur Leitung von Patienten- und Angehörigengruppen. Elsevier GmbH, Urban & Fischer, München/Jena

    Google Scholar 

  113. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148(2):224–230

    CAS  PubMed  Google Scholar 

  114. Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ (2006) Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res 86(1–3):251–255

    Article  CAS  PubMed  Google Scholar 

  115. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA (2006) Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194(3):164–172

    Article  PubMed  Google Scholar 

  116. Wisdom JP, Manuel JI, Drake RE (2011) Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr Serv 62(9):1007–1012

    Article  PubMed  PubMed Central  Google Scholar 

  117. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63(10):892–909

    Article  PubMed  Google Scholar 

  118. Potvin S, Blanchet P, Stip E (2009) Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res 113(2–3):181–188

    Article  PubMed  Google Scholar 

  119. Richard ML, Liskow BI, Perry PJ (1985) Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 46(3):79–83

    CAS  PubMed  Google Scholar 

  120. Siris SG (1990) Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16(1):111–122

    Article  CAS  PubMed  Google Scholar 

  121. Kosten TR, Kleber HD (1988) Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 14(3):335–346

    Article  CAS  PubMed  Google Scholar 

  122. NICE (2011) Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings. https://www.nice.org.uk/guidance/cg120/resources/coexisting-severe-mental-illness-psychosis-and-substance-misuse-assessment-and-management-in-healthcare-settings-pdf-35109443184325

  123. NICE (2014) NICE clinical guideline 178 – psychosis and schizophrenia in adults: treatment and management – issued: February 2014 last modified: March 2014. guidance.nice.org.uk/cg178

  124. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M (2013) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 10:CD001088

    Google Scholar 

  125. Crockford D, Addington D (2017) Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatr 62(9):624–634

    Article  Google Scholar 

  126. Wobrock T, Soyka M (2009) Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opin Pharmacother 10(3):353–367

    Article  CAS  PubMed  Google Scholar 

  127. Wobrock T, Soyka M (2008) Pharmacotherapy of schizophrenia with comorbid substance use disorder – reviewing the evidence and clinical recommendations. Prog Neuro-Psychopharmacol Biol Psychiatry 32(6):1375–1385

    Article  CAS  Google Scholar 

  128. Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompre PP, Potvin S (2010) Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol 30(4):417–424

    Article  CAS  PubMed  Google Scholar 

  129. Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11–24

    Article  PubMed  Google Scholar 

  130. Alper K, Schwartz KA, Kolts RL, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62(4):345–354

    Article  PubMed  Google Scholar 

  131. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387(10037):2507–2520

    Article  CAS  PubMed  Google Scholar 

  132. Roberts E, Eden Evins A, McNeill A, Robson D (2016) Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction 111(4):599–612

    Article  PubMed  PubMed Central  Google Scholar 

  133. Hill M (2015) Perspective: be clear about the real risks. Nature 525(7570):S14

    Article  CAS  PubMed  Google Scholar 

  134. Murray RM, Di Forti M (2016) Cannabis and psychosis: what degree of proof do we require? Biol Psychiatry 79(7):514–515

    Article  PubMed  Google Scholar 

  135. Gage SH, Jones HJ, Burgess S, Bowden J, Davey Smith G, Zammit S, Munafo MR (2017) Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med 47(5):971–980

    Article  CAS  PubMed  Google Scholar 

  136. Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79(7):549–556

    Article  PubMed  Google Scholar 

  137. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42(5):1262–1269

    Article  PubMed  PubMed Central  Google Scholar 

  138. Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya S (2016) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3(3):215–225

    Article  PubMed  Google Scholar 

  139. Foglia E, Schoeler T, Klamerus E, Morgan K, Bhattacharyya S (2017) Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med 47(10):1691–1705

    Article  CAS  PubMed  Google Scholar 

  140. Marshall K, Gowing L, Ali R, Le Foll B (2014) Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 12:CD008940

    Google Scholar 

  141. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L (2016) Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 5:CD005336

    Google Scholar 

  142. Hoch E, Friemel CM, Schneider M (2019) Cannabis: Potenzial und Risiko – Eine wissenschaftliche Bestandsaufnahme. Springer, Berlin/Heidelberg

    Book  Google Scholar 

  143. Miller LJ (1997) Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 23(4):623–635

    Article  CAS  PubMed  Google Scholar 

  144. Tosato S, Albert U, Tomassi S, Iasevoli F, Carmassi C, Ferrari S, Nanni MG, Nivoli A, Volpe U, Atti AR, Fiorillo A (2017) A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry 78(5):e477–ee89

    Article  PubMed  Google Scholar 

  145. Bennedsen BE (1998) Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophr Res 33(1–2):1–26

    Article  CAS  PubMed  Google Scholar 

  146. Lin HC, Chen YH, Lee HC (2009) Prenatal care and adverse pregnancy outcomes among women with schizophrenia: a nationwide population-based study in Taiwan. J Clin Psychiatry 70(9):1297–1303

    Article  PubMed  Google Scholar 

  147. Galbally M, Snellen M, Power J (2014) Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf 5(2):100–109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81(1):1–13

    Article  PubMed  PubMed Central  Google Scholar 

  149. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071

    Article  CAS  PubMed  Google Scholar 

  150. Chisolm MS, Payne JL (2016) Management of psychotropic drugs during pregnancy. BMJ 532:h5918

    Article  CAS  PubMed  Google Scholar 

  151. Galbally M, Snellen M, Walker S, Permezel M (2010) Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 44(2):99–108

    Article  PubMed  Google Scholar 

  152. Gentile S (2010) Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36(3):518–544

    Article  PubMed  Google Scholar 

  153. Seeman MV (2013) Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand 127(1):12–22

    Article  CAS  PubMed  Google Scholar 

  154. Essali A, Alabed S, Guul A, Essali N (2013) Preventive interventions for postnatal psychosis. Schizophr Bull 39(4):748–750

    Article  PubMed  PubMed Central  Google Scholar 

  155. Webb RT, Howard L, Abel KM (2004) Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2:CD004411

    Google Scholar 

  156. Klinger G, Stahl B, Fusar-Poli P, Merlob P (2013) Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev 10(3):308–317

    PubMed  Google Scholar 

  157. McCauley-Elsom K, Gurvich C, Elsom SJ, Kulkarni J (2010) Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs 17(2):97–104

    Article  CAS  PubMed  Google Scholar 

  158. Hasan A, Falkai P (2016) Somatische Therapieverfahren. In: Falkai P (Hrsg) Praxishandbuch Schizophrenie, Bd 1. Elsevier, München, S 77–106

    Chapter  Google Scholar 

  159. Cohen LS, Viguera AC, McInerney KA, Freeman MP, Sosinsky AZ, Moustafa D, Marfurt SP, Kwiatkowski MA, Murphy SK, Farrell AM, Chitayat D, Hernandez-Diaz S (2016) Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National pregnancy registry for atypical antipsychotics. Am J Psychiatry 173(3):263–270

    Article  PubMed  Google Scholar 

  160. Paulzen M, Benkert O (2017) Psychopharmaka in Schwangerschaft und Stillzeit. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd 17. Springer, Berlin/Heidelberg, S 902–930

    Chapter  Google Scholar 

  161. FDA (2015) Pregnancy and lactation labeling (drugs) final rule. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/labeling/ucm093307.htm

  162. FDA (2018) FDA pregnancy categories. https://chemm.nlm.nih.gov/pregnancycategories.htm

  163. Mehta TM, Van Lieshout RJ (2017) A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health 20(1):1–9

    Article  PubMed  Google Scholar 

  164. Fortinguerra F, Clavenna A, Bonati M (2009) Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics 124(4):e547–e556

    Article  PubMed  Google Scholar 

  165. Gentile S (2008) Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry 69(4):666–673

    Article  CAS  PubMed  Google Scholar 

  166. Anderson EL, Reti IM (2009) ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 71(2):235–242

    Article  PubMed  Google Scholar 

  167. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Hoie B (2015) Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health 18(1):1–39

    Article  PubMed  Google Scholar 

  168. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2(5):e141

    Article  PubMed  PubMed Central  Google Scholar 

  169. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R (1986) Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med 16(4):909–928

    Article  CAS  PubMed  Google Scholar 

  170. McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76

    Article  PubMed  Google Scholar 

  171. Abel KM, Drake R, Goldstein JM (2010) Sex differences in schizophrenia. Int Rev Psychiatry. 22(5):417–428

    Article  PubMed  Google Scholar 

  172. Angermeyer MC, Kuhn L (1988) Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 237(6):351–364

    Article  CAS  PubMed  Google Scholar 

  173. Häfner H (2000) Gender differences in schizophreni. In: Frank B (Hrsg) Gender and its effects on psychopathology. American Psychiatric Press, Washington, DC, S 187–228

    Google Scholar 

  174. Riecher-Rossler A, Hafner H (1993) Schizophrenia and oestrogens – is there an association? Eur Arch Psychiatry Clin Neurosci 242(6):323–328

    Article  CAS  PubMed  Google Scholar 

  175. Hafner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):17–54

    Article  PubMed  Google Scholar 

  176. Seeman MV (2012) Women and psychosis. Womens Health 8(2):215–224

    Google Scholar 

  177. Seeman MV (1986) Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 73(6):609–617

    Article  CAS  PubMed  Google Scholar 

  178. Halbreich U, Kahn LS (2003) Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 28(Suppl 2):1–16

    CAS  PubMed  Google Scholar 

  179. Heringa SM, Begemann MJ, Goverde AJ, Sommer IE (2015) Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr Res 168(3):603–613

    Article  PubMed  Google Scholar 

  180. Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Stauffer V, Menard F, Kinon BJ, Kapur S (2014) Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry 75(4):e308–e316

    Article  CAS  PubMed  Google Scholar 

  181. Crawford MB, DeLisi LE (2016) Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry 29(3):211–217

    Article  PubMed  Google Scholar 

  182. NICE (2013) Psychosis and schizophrenia in children and young people: recognition and management. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0078141/pdf/PubMedHealth_PMH0078141.pdf

  183. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM (1976) A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 19(1):99–104

    CAS  PubMed  Google Scholar 

  184. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141(3):440–442

    Article  CAS  PubMed  Google Scholar 

  185. Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28(2):183–186

    CAS  PubMed  Google Scholar 

  186. Pagsberg AK, Tarp S, Glintborg D, Stenstrom AD, Fink-Jensen A, Correll CU, Christensen R (2017) Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56(3):191–202

    Article  PubMed  Google Scholar 

  187. Harvey RC, James AC, Shields GE (2016) A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 30(1):27–39

    Article  CAS  PubMed  Google Scholar 

  188. Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G (2003) Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110(5):545–560

    Article  CAS  PubMed  Google Scholar 

  189. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC (2008) A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18(4):317–326

    Article  PubMed  Google Scholar 

  190. Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D (2015) Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry 54(2):126–137. e1

    Article  PubMed  Google Scholar 

  191. Findling RL, Landbloom RP, Mackle M, Pallozzi W, Braat S, Hundt C, Wamboldt MZ, Mathews M (2015) Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 25(5):384–396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM (2010) A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol 25(1):1–6

    Article  PubMed  Google Scholar 

  193. Goldman R, Loebel A, Cucchiaro J, Deng L, Findling RL (2017) Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol 27(6):516–525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Ruda D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrom AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-Jensen A (2017) Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry 4(8):605–618

    Article  PubMed  Google Scholar 

  195. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 26(2):219–230

    Article  PubMed  Google Scholar 

  196. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, group Cg (2011) Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 20(3):218–233

    PubMed  PubMed Central  Google Scholar 

  197. Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M (2016) Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacol 26(5):458–470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Correll CU (2008) Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69(Suppl 4):26–36

    CAS  PubMed  Google Scholar 

  199. Schimmelmann BG, Paulus S, Schacht M, Tilgner C, Schulte-Markwort M, Lambert M (2005) Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 15(2):249–258

    Article  PubMed  Google Scholar 

  200. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL (1996) Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53(12):1090–1097

    Article  CAS  PubMed  Google Scholar 

  201. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63(7):721–730

    Article  CAS  PubMed  Google Scholar 

  202. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM (2008) Clozapine and „high-dose“ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63(5):524–529

    Article  PubMed  Google Scholar 

  203. Schneider C, Papachristou E, Wimberley T, Gasse C, Dima D, MacCabe JH, Mortensen PB, Frangou S (2015) Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol 25(6):857–863

    Article  CAS  PubMed  Google Scholar 

  204. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201(6):481–485

    Article  PubMed  Google Scholar 

  205. Trinczek E, Heinzel-Gutenbrunner M, Haberhausen M, Bachmann CJ (2016) Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia. Pharmacopsychiatry 49(6):254–259

    Article  CAS  PubMed  Google Scholar 

  206. Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, Kendall T (2015) Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS ONE 10(2):e0117166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Calvo A, Moreno M, Ruiz-Sancho A, Rapado-Castro M, Moreno C, Sanchez-Gutierrez T, Arango C, Mayoral M (2015) Psychoeducational group intervention for adolescents with psychosis and their families: a two-year follow-up. J Am Acad Child Adolesc Psychiatry 54(12):984–990

    Article  PubMed  Google Scholar 

  208. Calvo A, Moreno M, Ruiz-Sancho A, Rapado-Castro M, Moreno C, Sanchez-Gutierrez T, Arango C, Mayoral M (2014) Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 53(6):688–696

    Article  PubMed  Google Scholar 

  209. Jackson C, Trower P, Reid I, Smith J, Hall M, Townend M, Barton K, Jones J, Ross K, Russell R, Newton E, Dunn G, Birchwood M (2009) Improving psychological adjustment following a first episode of psychosis: a randomised controlled trial of cognitive therapy to reduce post psychotic trauma symptoms. Behav Res Ther 47(6):454–462

    Article  CAS  PubMed  Google Scholar 

  210. Jackson HJ, McGorry PD, Killackey E, Bendall S, Allott K, Dudgeon P, Gleeson J, Johnson T, Harrigan S (2008) Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. Psychol Med 38(5):725–735

    Article  CAS  PubMed  Google Scholar 

  211. Mak GKL, Li FWS, Lee PWH (2007) A pilot study on psychological interventions with Chinese young adults with schizophrenia. Hong Kong J Psychiatry 17(1):17–23

    Google Scholar 

  212. Power PJ, Bell RJ, Mills R, Herrman-Doig T, Davern M, Henry L, Yuen HP, Khademy-Deljo A, McGorry PD (2003) Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust N Z J Psychiatry 37(4):414–420

    Article  CAS  PubMed  Google Scholar 

  213. Linszen D, Dingemans P, Van der Does JW, Nugter A, Scholte P, Lenior R, Goldstein MJ (1996) Treatment, expressed emotion and relapse in recent onset schizophrenic disorders. Psychol Med 26(2):333–342

    Article  CAS  PubMed  Google Scholar 

  214. Gleeson JF, Cotton SM, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, Pearce T, Newman B, Spiliotacopoulos D, Castle D, McGorry PD (2009) A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J Clin Psychiatry 70(4):477–486

    Article  PubMed  Google Scholar 

  215. Gleeson JF, Cotton SM, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, Pearce T, Spiliotacopoulos D, Newman B, McGorry PD (2013) A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull 39(2):436–448

    Article  PubMed  Google Scholar 

  216. McFarlane WR, Levin B, Travis L, Lucas FL, Lynch S, Verdi M, Williams D, Adelsheim S, Calkins R, Carter CS, Cornblatt B, Taylor SF, Auther AM, McFarland B, Melton R, Migliorati M, Niendam T, Ragland JD, Sale T, Salvador M, Spring E (2015) Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull 41(1):30–43

    Article  PubMed  Google Scholar 

  217. Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, Schlosser D, Pham L, Miskovich T, Vinogradov S (2015) Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull 41(1):250–258

    Article  PubMed  Google Scholar 

  218. Wachtel LE, Dhossche DM, Kellner CH (2011) When is electroconvulsive therapy appropriate for children and adolescents? Med Hypotheses 76(3):395–399

    Article  PubMed  Google Scholar 

  219. Lima NN, Nascimento VB, Peixoto JA, Moreira MM, Neto ML, Almeida JC, Vasconcelos CA, Teixeira SA, Junior JG, Junior FT, Guimaraes DD, Brasil AQ, Cartaxo JS, Akerman M, Reis AO (2013) Electroconvulsive therapy use in adolescents: a systematic review. Ann General Psychiatry 12(1):17

    Article  Google Scholar 

  220. Shoirah H, Hamoda HM (2011) Electroconvulsive therapy in children and adolescents. Expert Rev Neurother 11(1):127–137

    Article  PubMed  Google Scholar 

  221. Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC (2010) Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep 12(1):28–33

    Article  PubMed  Google Scholar 

  222. Benkert O, Hippius H (2013) Psychopharmaka im Alter und bei internistischen Erkrankungen. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd 9. Springer, Berlin/Heidelberg

    Google Scholar 

  223. Broadway J, Mintzer J (2007) The many faces of psychosis in the elderly. Curr Opin Psychiatry 20(6):551–558

    Article  PubMed  Google Scholar 

  224. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M (2008) Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 16(7):584–593

    Article  PubMed  Google Scholar 

  225. Howard R, Rabins PV, Seeman MV, Jeste DV (2000) Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 157(2):172–178

    Article  CAS  PubMed  Google Scholar 

  226. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410–472

    Article  PubMed  Google Scholar 

  227. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM (2001) Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 58(6):565–572

    Article  CAS  PubMed  Google Scholar 

  228. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC (2011) Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging 28(12):961–980

    Article  CAS  PubMed  Google Scholar 

  229. Essali A, Ali G (2012) Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2:CD004162

    Google Scholar 

  230. Marriott RG, Neil W, Waddingham S (2006) Antipsychotic medication for elderly people with schizophrenia. Cochrane Database Syst Rev 1:CD005580

    Google Scholar 

  231. Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older P (2004) Using antipsychotic agents in older patients. J Clin Psychiatry 65(Suppl 2):5–99; discussion 100–102; quiz 3–4

    PubMed  Google Scholar 

  232. Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu AV, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Gray R (2018) Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry 5(7):553–563

    Article  PubMed  PubMed Central  Google Scholar 

  233. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E (2010) Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 197(5):350–356

    Article  PubMed  PubMed Central  Google Scholar 

  234. Birchwood M, Todd P, Jackson C (1998) Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172(33):53–59

    Article  CAS  PubMed  Google Scholar 

  235. Lambert M, Schöttle D, Sengutta M, Lüdecke D, Nawara AL, Galling B, Handwerk U, Rothländer W, Falk AL, Rietschel L, Gagern C, Sarikaya G, Wittmann L, Ruppelt F, Daubmann A, Lange B, Naber D, Schulte-Markwort M, Unger HP, Ott S, Romer G, Krüger H, Gallinat J, Wegscheider K, Bock T, Karow A (2015) Early detection and integrated care in adolescents and young adults with severe psychotic illnesses. Psychiatr Prax 42(Suppl1):S49–S53

    PubMed  Google Scholar 

  236. Leopold K, Nikolaides A, Bauer M, Bechdolf A, Correll CU, Jessen F, Juckel G, Karow A, Lambert M, Klosterkotter J, Ruhrmann S, Pfeiffer S, Pfennig A (2015) [Services for the early recognition of psychoses and bipolar disorders in Germany: inventory survey study]. Nervenarzt 86(3):352–358

    Google Scholar 

  237. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62(9):975–983

    Article  PubMed  Google Scholar 

  238. Norman RM, Lewis SW, Marshall M (2005) Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry Suppl 48:s19–s23

    Article  PubMed  Google Scholar 

  239. Penttila M, Jaaskelainen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205(2):88–94

    Article  PubMed  Google Scholar 

  240. Lloyd-Evans B, Crosby M, Stockton S, Pilling S, Hobbs L, Hinton M, Johnson S (2011) Initiatives to shorten duration of untreated psychosis: systematic review. Br J Psychiatry 198(4):256–263

    Article  PubMed  Google Scholar 

  241. Friis S, Melle I, Johannessen JO, Rossberg JI, Barder HE, Evensen JH, Haahr U, Ten Velden Hegelstad W, Joa I, Langeveld J, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PW, McGlashan TH (2016) Early predictors of ten-year course in first-episode psychosis. Psychiatr Serv 67(4):438–443

    Article  PubMed  Google Scholar 

  242. Birchwood M, McGorry P, Jackson H (1997) Early intervention in schizophrenia. Br J Psychiatry 170:2–5

    Article  CAS  PubMed  Google Scholar 

  243. Lieberman JA, Fenton WS (2000) Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 157(11):1727–1730

    Article  CAS  PubMed  Google Scholar 

  244. Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig T, Nordentoft M, Srihari VH, Guloksuz-Hui CLM, Chen EYM, Valencia M, Robinson J, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe J, Kane J (2018) Effectiveness of coordinated specialty care for early psychosis: systematic review, meta-analysis, and metaregression-analysis submitted to journal (Persönliche Kommunikation)

    Google Scholar 

  245. Lambert M, Schottle D, Ruppelt F, Ludecke D, Sarikaya G, Schulte-Markwort M, Gallinat J, Karow A (2015) Integrated care for patients with first and multiple episodes of severe psychotic illnesses: 3-year results of the Hamburg model. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 58(4–5):408–419

    Article  Google Scholar 

  246. Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S (2017) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9):694–705

    Article  PubMed  Google Scholar 

  247. Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, Schneider-Thoma J, Leucht S (2017) How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 27(9):835–844

    Article  CAS  PubMed  Google Scholar 

  248. Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ (2000) The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 48(6):467–476

    Article  CAS  PubMed  Google Scholar 

  249. Lieberman JA, Stroup TS (2003) Schizophrenia, VI: treatments. Am J Psychiatry 160(10):1748

    Article  PubMed  Google Scholar 

  250. Addington J, Leriger E, Addington D (2003) Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatr 48(3):204–207

    Article  Google Scholar 

  251. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS, group Es (2009) Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 115(2–3):97–103

    Article  PubMed  Google Scholar 

  252. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE, group Es (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085–1097

    Article  CAS  PubMed  Google Scholar 

  253. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162(3):441–449

    Article  PubMed  Google Scholar 

  254. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609

    Article  PubMed  Google Scholar 

  255. Coldham EL, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106(4):286–290

    Article  CAS  PubMed  Google Scholar 

  256. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56(3):241–247

    Article  CAS  PubMed  Google Scholar 

  257. Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13(3):663–670

    Article  CAS  PubMed  Google Scholar 

  258. Gafoor R, Nitsch D, McCrone P, Craig TK, Garety PA, Power P, McGuire P (2010) Effect of early intervention on 5-year outcome in non-affective psychosis. Br J Psychiatry 196(5):372–376

    Article  PubMed  Google Scholar 

  259. Bechdolf A, Pohlmann B, Guttgemanns J, Geyer C, Lindner K, Ferber C, Gouzoulis-Mayfrank E (2012) State-dependent motivational interviewing for people with schizophrenia and substance use: results of a randomised controlled trial. Nervenarzt 83(7):888–896

    Article  CAS  PubMed  Google Scholar 

  260. Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, Operskalski BH, Penfold RB, Hunkeler EM (2018) Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 75(3):254–260

    Article  PubMed  PubMed Central  Google Scholar 

  261. Ramsay CE, Broussard B, Goulding SM, Cristofaro S, Hall D, Kaslow NJ, Killackey E, Penn D, Compton MT (2011) Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis. Psychiatry Res 189(3):344–348

    Article  PubMed  PubMed Central  Google Scholar 

  262. Bond GR, Drake RE, Campbell K (2016) Effectiveness of individual placement and support supported employment for young adults. Early Interv Psychiatry 10(4):300–307

    Article  PubMed  Google Scholar 

  263. Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Meyer-Kalos PS, Gottlieb JD, Glynn SM, Lynde DW, Pipes R, Kurian BT, Miller AL, Azrin ST, Goldstein AB, Severe JB, Lin H, Sint KJ, John M, Heinssen RK (2016) Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the nimh raise early treatment program. Am J Psychiatry 173(4):362–372

    Article  PubMed  Google Scholar 

  264. Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J (1978) Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry 13(2):100–111

    Article  CAS  PubMed  Google Scholar 

  265. Bola JR, Mosher LR (2003) Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis 191(4):219–229

    PubMed  Google Scholar 

  266. McGorry P, Francey S, Nelson B, Jessica G, Lara B, Suzy H, Pan Yuen H, Alex F, Kelly A, Mario A-J, Brian OD (2018) T119. CAN some young people recover from first-episode psychosis with integrated psychosocial treatment without antipsychotic medications? AN RCT to assess risks, benefits, and range of outcomes. Schizophr Bull 44(Suppl 1):S162

    Article  PubMed Central  Google Scholar 

  267. Bola JR, Lehtinen K, Cullberg J, Ciompi L (2009) Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: a review of the literature. Psychosis 1(1):4–18

    Article  Google Scholar 

  268. Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe JB, Kane JM (2018) Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 75(6):555–565

    Article  PubMed  PubMed Central  Google Scholar 

  269. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71(12):1350–1363

    Article  PubMed  Google Scholar 

  270. Hafner H, Maurer K, an der Heiden W (2013) ABC Schizophrenia study: an overview of results since 1996. Soc Psychiatry Psychiatr Epidemiol 48(7):1021–1031

    Article  CAS  PubMed  Google Scholar 

  271. Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkotter J (2015) EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 30(3):405–416

    Article  CAS  PubMed  Google Scholar 

  272. Klosterkotter J (2014) Prediction of psychoses. Nervenarzt 85(10):1238–1248

    Article  CAS  PubMed  Google Scholar 

  273. Gaebel W (2012) Status of psychotic disorders in ICD-11. Schizophr Bull 38(5):895–898

    Article  PubMed  PubMed Central  Google Scholar 

  274. Carpenter WT, van Os J (2011) Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry 168(5):460–463

    Article  PubMed  Google Scholar 

  275. Gaebel W, Zielasek J, Cleveland HR (2013) Psychotic disorders in ICD-11. Asian J Psychiatr 6(3):263–265

    Article  PubMed  Google Scholar 

  276. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD (2006) Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 84(1):57–66

    Article  PubMed  Google Scholar 

  277. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29(4):703–715

    Article  PubMed  Google Scholar 

  278. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, Schimmelmann BG, Klosterkotter J (2012) Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des 18(4):351–357

    Article  CAS  PubMed  Google Scholar 

  279. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH (2014) Attenuated psychosis syndrome: ready for DSM-5.1? Annu Rev Clin Psychol 10:155–192

    Article  CAS  PubMed  Google Scholar 

  280. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkotter J, McGuire P, Yung A (2013) The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70(1):107–120

    Article  PubMed  PubMed Central  Google Scholar 

  281. Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, McGuire P (2013) At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 39(4):923–932

    Article  PubMed  Google Scholar 

  282. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168(8):800–805

    Article  PubMed  PubMed Central  Google Scholar 

  283. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR (2015) Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 172(3):249–258

    Article  PubMed  Google Scholar 

  284. Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkotter J (2010) Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci 260(Suppl 2):S90–S94

    Article  PubMed  Google Scholar 

  285. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 39(11–12):964–971

    Article  PubMed  Google Scholar 

  286. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkotter J (2007) Schizophrenia proneness instrument adult version (SPI-A). Giovanni Fioriti Editore, Rome

    Google Scholar 

  287. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkotter J, Ruhrmann S (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30(3):388–404

    Article  CAS  PubMed  Google Scholar 

  288. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59(10):921–928

    Article  PubMed  Google Scholar 

  289. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163(5):790–799

    Article  PubMed  Google Scholar 

  290. Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Hafner H, Gaebel W, Moller HJ, Maier W, Klosterkotter J, group Ls (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:s88–s95

    Article  CAS  PubMed  Google Scholar 

  291. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, Berger GE, Amminger GP, Simmons MB, Kelly D, Dip G, Thompson AD, Yung AR (2013) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 74(4):349–356

    Article  CAS  PubMed  Google Scholar 

  292. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96–s101

    Article  PubMed  Google Scholar 

  293. Tsujino N, Nemoto T, Morita K, Katagiri N, Ito S, Mizuno M (2013) Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial. Clin Psychopharmacol Neurosci 11(3):132–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  294. Schultze-Lutter F, Schimmelmann BG, Klosterkotter J, Ruhrmann S (2012) Comparing the prodrome of schizophrenia-spectrum psychoses and affective disorders with and without psychotic features. Schizophr Res 138(2–3):218–222

    Article  PubMed  Google Scholar 

  295. Schimmelmann BG, Schultze-Lutter F (2012) Early detection and intervention of psychosis in children and adolescents: urgent need for studies. Eur Child Adolesc Psychiatry 21(5):239–241

    Article  PubMed  Google Scholar 

  296. Schimmelmann BG, Walger P, Schultze-Lutter F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatr 58(1):32–40

    Article  Google Scholar 

  297. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69(3):220–229

    Article  PubMed  Google Scholar 

  298. Bartels-Velthuis AA, van de Willige G, Jenner JA, van Os J, Wiersma D (2011) Course of auditory vocal hallucinations in childhood: 5-year follow-up study. Br J Psychiatry 199(4):296–302

    Article  PubMed  Google Scholar 

  299. Brandizzi M, Schultze-Lutter F, Masillo A, Lanna A, Curto M, Lindau JF, Solfanelli A, Listanti G, Patane M, Kotzalidis G, Gebhardt E, Meyer N, Di Pietro D, Leccisi D, Girardi P, Fiori Nastro P (2014) Self-reported attenuated psychotic-like experiences in help-seeking adolescents and their association with age, functioning and psychopathology. Schizophr Res 160(1–3):110–117

    Article  PubMed  Google Scholar 

  300. Kelleher I, Keeley H, Corcoran P, Lynch F, Fitzpatrick C, Devlin N, Molloy C, Roddy S, Clarke MC, Harley M, Arseneault L, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M (2012) Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. Br J Psychiatry 201(1):26–32

    Article  PubMed  Google Scholar 

  301. Schimmelmann BG, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter F (2015) Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychiatry 14(2):189–197

    Article  PubMed  PubMed Central  Google Scholar 

  302. Schultze-Lutter F, Hubl D, Schimmelmann BG, Michel C (2017) Age effect on prevalence of ultra-high risk for psychosis symptoms: replication in a clinical sample of an early detection of psychosis service. Eur Child Adolesc Psychiatry 26(11):1401–1405

    Article  PubMed  Google Scholar 

  303. Fux L, Walger P, Schimmelmann BG, Schultze-Lutter F (2013) The schizophrenia proneness instrument, child and youth version (SPI-CY): practicability and discriminative validity. Schizophr Res 146(1–3):69–78

    Article  PubMed  Google Scholar 

  304. Kompus K, Loberg EM, Posserud MB, Lundervold AJ (2015) Prevalence of auditory hallucinations in Norwegian adolescents: results from a population-based study. Scand J Psychol 56(4):391–396

    Article  PubMed  PubMed Central  Google Scholar 

  305. Cornblatt BA, Carrion RE, Auther A, McLaughlin D, Olsen RH, John M, Correll CU (2015) Psychosis prevention: a modified clinical high risk perspective from the recognition and prevention (rap) program. Am J Psychiatry 172(10):986–994

    Article  PubMed  PubMed Central  Google Scholar 

  306. Armando M, Pontillo M, De Crescenzo F, Mazzone L, Monducci E, Lo Cascio N, Santonastaso O, Pucciarini ML, Vicari S, Schimmelmann BG, Schultze-Lutter F (2015) Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents. Schizophr Res 169(1–3):186–192

    Article  PubMed  Google Scholar 

  307. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149(1–3):56–62

    Article  PubMed  Google Scholar 

  308. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Moller HJ, Gaebel W, Hafner H, Maier W, Klosterkotter J (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200(1):22–29

    Article  CAS  PubMed  Google Scholar 

  309. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, Krarup G, Jorgensen P, Jeppesen P (2006) Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 83(1):29–40

    Article  PubMed  Google Scholar 

  310. Miklowitz DJ, O’Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD (2014) Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 53(8):848–858

    Article  PubMed  PubMed Central  Google Scholar 

  311. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67(2):146–154

    Article  CAS  PubMed  Google Scholar 

  312. McGorry PD, Nelson B, Markulev C, Yuen HP, Schafer MR, Mossaheb N, Schlogelhofer M, Smesny S, Hickie IB, Berger GE, Chen EY, de Haan L, Nieman DH, Nordentoft M, Riecher-Rossler A, Verma S, Thompson A, Yung AR, Amminger GP (2017) Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 74(1):19–27

    Article  PubMed  Google Scholar 

  313. Gaebel W, Zielasek J (2011) Integrative etiopathogenetic models of psychotic disorders: methods, evidence and concepts. Schizophr Bull 37(Suppl 2):S5–S12

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät (federführend), Düsseldorf, Deutschland

    Prof. Dr. Wolfgang Gaebel

  2. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Deutschland

    Prof. Dr. Alkomiet Hasan & Prof. Dr. Peter Falkai

Authors
  1. Prof. Dr. Wolfgang Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Alkomiet Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Peter Falkai
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät (federführend), Düsseldorf, Germany

    Wolfgang Gaebel

  2. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Germany

    Alkomiet Hasan

  3. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Germany

    Peter Falkai

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN)

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gaebel, W., Hasan, A., Falkai, P. (2019). Behandlung unter besonderen Bedingungen (Modul 4c). In: Gaebel, W., Hasan, A., Falkai, P. (eds) S3-Leitlinie Schizophrenie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59380-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59380-6_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59379-0

  • Online ISBN: 978-3-662-59380-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation